Skandinaviska Enskilda Banken (SEB)
SMMT icon

Skandinaviska Enskilda Banken (SEB)’s Summit Therapeutics SMMT Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-338,363
Closed -$5.91M – 622
2025
Q4 		$5.91M Hold
338,363
– – 0.02% 382
2025
Q3 		$6.99M Buy
338,363
+271,912
+409% +$6.59M 0.03% 347
2025
Q2 		$1.41M Hold
66,451
– – 0.01% 622
2025
Q1 		$1.28M Buy
66,451
+33,788
+103% +$678K 0.01% 618
2024
Q4 		$586K Buy
+32,663
New +$633K ﹤0.01% 703

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s SMMT Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 338,363 shares — an estimated $5.91M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in SMMT in Q4 2024 and held it in 5 quarters. The position peaked at $6.99M in Q3 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 338,363 Summit Therapeutics shares in Q1 2026, an estimated $5.91M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Summit Therapeutics in Q4 2024 and held it in 5 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Summit Therapeutics position peaked at $6.99M in Q3 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.